Pharvaris Presents Clinical and Non-Clinical Data Supporting HAE Development Program at the 2024 ACAAI Annual Scientific Meeting
PHVS Stock | USD 19.43 0.07 0.36% |
Slightly above 62% of Pharvaris' investor base is looking to short. The analysis of overall sentiment of trading Pharvaris BV stock suggests that many investors are alarmed at this time. Pharvaris' investing sentiment can be driven by a variety of factors including economic data, Pharvaris' earnings reports, geopolitical events, and overall market trends.
Pharvaris |
Data from randomized clinical studies and long-term extension studies support deucrictibants potential best-in-class profile, detailing its injectable-like efficacy, placebo-like tolerability, and oral convenienceZUG, Switzerland, Oct. 24, 2024 -- Pharvaris , a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat hereditary angioedema attacks, today announced data from seven posters that will be
Read at finance.yahoo.com
![]() |
Pharvaris Fundamental Analysis
We analyze Pharvaris' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Pharvaris using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Pharvaris based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Cash And Equivalents
Cash And Equivalents Comparative Analysis
Pharvaris is currently under evaluation in cash and equivalents category among its peers. Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Pharvaris BV Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Pharvaris stock to make a market-neutral strategy. Peer analysis of Pharvaris could also be used in its relative valuation, which is a method of valuing Pharvaris by comparing valuation metrics with similar companies.
Peers
Pharvaris Related Equities
ANEB | Anebulo Pharmaceuticals | 4.94 | ||||
ANTX | AN2 Therapeutics | 4.35 | ||||
MNOV | MediciNova | 1.93 | ||||
GLUE | Monte Rosa | 0.57 | ||||
PMVP | Pmv Pharmaceuticals | 0.66 | ||||
RZLT | Rezolute | 1.00 | ||||
DSGN | Design Therapeutics | 1.28 | ||||
STOK | Stoke Therapeutics | 1.60 | ||||
IKNA | Ikena Oncology | 1.91 | ||||
JANX | Janux Therapeutics | 1.94 | ||||
HOWL | Werewolf Therapeutics | 2.52 | ||||
TYRA | Tyra Biosciences | 4.29 | ||||
MLYS | Mineralys Therapeutics, | 4.52 | ||||
MOLN | Molecular Partners | 5.85 | ||||
PEPG | PepGen | 8.41 |
Additional Tools for Pharvaris Stock Analysis
When running Pharvaris' price analysis, check to measure Pharvaris' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pharvaris is operating at the current time. Most of Pharvaris' value examination focuses on studying past and present price action to predict the probability of Pharvaris' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pharvaris' price. Additionally, you may evaluate how the addition of Pharvaris to your portfolios can decrease your overall portfolio volatility.